Table 6.
Diagnostic performance of 2D-SWE for liver fibrosis in patients with CHB
| Cross-sectional study | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | No. of patients | Nation | Significant fibrosis (≥F2) |
Advanced fibrosis (≥F3) |
Cirrhosis (F4) |
|||||||||
| No. of patients (%) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | No. of patients (%) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | No. of patients (%) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | |||
| Leung et al. [134] (2013) | 226 | China | 136 (60.2) | 0.88 (0.82–0.94) | 7.1 | 84.7/92.1 | 80 (35.4) | 0.93 (0.88–0.97) | 7.9 | 89.8/90.3 | 35 (15.5) | 0.98 (0.95–0.99) | 10.1 | 97.4/93.0 |
| Zeng et al. [135] (2014) | 206 | China | 112 (54.4) | 0.92 (0.88–0.96) | 7.2 | 86.4/87.0 | 64 (31.1) | 0.95 (0.92–0.97) | 9.1 | 91.9/85.7 | 39 (18.9) | 0.95 (0.91–0.98) | 11.7 | 91.9/85.7 |
| Zheng et al. [136] (2015) | 167 | China | 98 (58.7) | 0.86 (0.80–0.91) | 8.0 | 85.7/73.9 | 58 (34.7) | - | - | - | 34 (20.4) | 0.93 (0.88–0.96) | 21.4 | 91.2/79.7 |
| Wu et al. [137] (2016) | 437 | China | 206 (47.1) | 0.90 (0.87–0.93) | 8.2 | 78.2/85.3 | 123 (28.1) | - | - | - | 61 (14.0) | 0.93 (0.90–0.95) | 11.3 | 91.8/84.3 |
| Zhuang et al. [138] (2017) | 304 | China | 264 (86.8) | 0.97 (0.95–0.99) | 7.6 | 92.0/90.0 | 214 (70.4) | 0.96 (0.94–0.99) | 9.2 | 91.6/96.7 | 167 (54.9) | 0.98 (0.97–1.00) | 10.4 | 94.6/94.9 |
| Zeng et al. [139] (2017) | 257 | China | 119 (46.3) | 0.88 (0.83–0.92) | 7.1 | 88.9/76.4 | 64 (24.9) | 0.92 (0.87–0.95) | 8.3 | 89.7/76.8 | 34 (13.2) | 0.93 (0.89–0.96) | 11.3 | 93.6/87.3 |
| Xie et al. [140] (2021) | 161 | China | 130 (80.7) | 0.92 (0.87–0.96) | 7.3 | 83.1/87.1 | 84 (52.2) | 0.92 (0.86–0.95) | 8.0 | 94.1/77.9 | 64 (39.8) | 0.94 (0.89–0.97) | 10.0 | 90.6/89.7 |
| Song et al. [141] (2023) | 420 | China | 306 (72.9) | 0.89 (0.85–0.92) | 6.9 | 77.0/86.0 | 227 (54.0) | 0.91 (0.88–0.94) | 7.4 | 80.0/86.0 | 134 (31.9) | 0.83 (0.79–0.87) | 8.0 | 81.0/73.0 |
|
Meta-analysis
| ||||||||||||||
| Reference | No. of patients | No. of studies |
Significant fibrosis (≥F2)
|
Advanced fibrosis (≥F3)
|
Cirrhosis (F4)
|
|||||||||
| No. of studies (patients) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | No. of studies (patients) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | No. of studies (patients) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | |||
| Herrmann et al. [144] (2018) | 400 | 4 | 4 (400) | 0.91 | 7.1 | 87.6/73.6 | 4 (400) | 0.93 | 8.1 | 94.9/73.1 | 4 (400) | 0.96 | 11.5 | 79.9/93.3 |
| Wei et al. [142] (2020) | 2,623 | 11 | - | 0.92 (0.89–0.94) | 7.9 | 88.0/83.0 | - | - | - | - | - | - | - | - |
| Dong et al. [143] (2021) | 3,085 | 13 | 13 (1,716) | 0.89 (0.86–0.92) | 7.6 | 80.9/79.3 | 8 (1,020) | 0.95 (0.91–0.95) | 9.1 | 89.1/84.7 | 12 (782) | 0.94 (0.92–0.96) | 10.9 | 87.3/86.1 |
CHB, chronic hepatitis B; AUC, area under the curve; CI, confidence interval; kPa, kilopascal.